HER2-Positive (HER2 +) Breast Cancer

Identification and characterization of a potent and selective HUNK inhibitor for treatment of HER2+ breast cancer

“…HER2+ breast cancer makes up around 15–30% of breast cancer and is associated with poor patient outcomes. 1 Multiple HER2 inhibitors have been developed for the treatment of HER2+ breast cancer, however, resistance to these inhibitors develops over time. There are also multiple mechanisms of resistance such as alterations to HER2, mutations in downstream signaling pathways, and activation of bypass signaling pathways.…”